(343) Oliceridine (TRV130), a novel µ receptor G protein pathway selective modulator (µ-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. II: simulation of potential dosing regimens using a pharmacokinetic/pharmacodynamic (PK/PD) model.